Analgesic use and the risk for progression of chronic kidney disease
Purpose The chronic effect of various analgesics on the progression of chronic kidney disease (CKD) is inconclusive. There is also lack of information on the renal safety of selective cyclooxygenase‐2 (COX‐2) inhibitors. This study aimed to clarify the renal risk of analgesic use in CKD patients. Me...
Gespeichert in:
Veröffentlicht in: | Pharmacoepidemiology and drug safety 2010-07, Vol.19 (7), p.745-751 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Purpose
The chronic effect of various analgesics on the progression of chronic kidney disease (CKD) is inconclusive. There is also lack of information on the renal safety of selective cyclooxygenase‐2 (COX‐2) inhibitors. This study aimed to clarify the renal risk of analgesic use in CKD patients.
Methods
A cohort study using a nationally representative database randomly sampled from National Health Insurance (NHI) enrollees was performed. The study population included a total of 19,163 newly diagnosed CKD patients. Clinical conditions were defined by diagnostic codes and exposure information on analgesics was derived from service claims. Cox proportional hazard model was used to assess the association between analgesic use and the risk of progression to end stage renal disease (ESRD).
Results
CKD patients using acetaminophen, aspirin, and non‐selective non‐steroidal anti‐inflammatory drugs (NSAIDs) had an increased risk for ESRD with multivariable‐adjusted HRs (95%CIs) of 2.92 (2.47–3.45), 1.96 (1.62–2.36), and 1.56 (1.32–1.85), respectively. The trends toward higher risk with increasing exposure dose were significant for all classes of analgesics (all P for trend |
---|---|
ISSN: | 1053-8569 1099-1557 1099-1557 |
DOI: | 10.1002/pds.1962 |